Nashrah Mustafa

Nashrah Mustafa

Auto-generated profile, based on publicly available information

Nashrah Mustafa

School of Pharmacy, BRAC University, Dhaka, Bangladesh

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2026 in Biomarker Insights
Verified
Journal Article
Open access
NMNashrah Mustafa
Nashrah Mustafa
MTMehrin Haque Tanisha
Mehrin Haque Tanisha
FTFariha Tasneem
Fariha Tasneem
ASAyman Siddique
Ayman Siddique
ZAZubaier Ahmed
Zubaier Ahmed
FRFazle Rabbi
Fazle Rabbi
The increasing mortality from ovarian and lung cancers worldwide is largely due to late diagnosis and therapeutic resistance. Conventional biomarkers such as CA125 and CYFRA 21-1 lack the sensitivity or the specificity for monitoring real time disease progression or therapeutic response. This has prompted researchers to work on the development of relevant biomarkers that are minimally invasive for cancer diagnosis, prognosis and for therapeutic stratification. As such, liquid biopsies, which analyze tumor-derived components circulating in the blood including circulating tumor cells (CTCs), which are shed from primary or metastatic tumors into the bloodstream have emerged as a promising approach for detecting such cancers. This review critically analyzes the diagnostic and prognostic significance of CTCs in ovarian and lung cancers, highlighting technological advances, molecular characterization, and translational challenges associated with their clinical application. It briefly discusses the clinical utility of some biomarkers from liquid biopsies used in the diagnosis, prognosis as well as monitoring of ovarian and lung cancers with their detection methods. It highlights some of the relevant studies conducted in the field and finally it provides insights on the future of liquid biopsies. An extensive literature review analyzing papers between 2008 and 2026 was conducted using PubMed, Scopus, and Web of Science databases, that evaluated CTC detection methods, molecular profiling, and clinical outcomes in ovarian and lung cancer patients. Current literature reports that CTC enumeration and molecular characterization can provide significant insights into disease progression, therapeutic resistance and predict survival outcomes. Whilst the enrichment technologies such as CellSearch ® , ISET, and microfluidic platforms have enhanced detection sensitivity, variability in assay performance and lack of a clinical standardization impede proper implementation. CTCs represent a powerful liquid biopsy tool with potential to revolutionize cancer diagnostics and precision medicine. Integration of multi-omics profiling, CTC-derived organoids, and AI-driven analytical models may further enhance their clinical utility in guiding personalized treatment strategies for ovarian and lung cancer patients.

1 January 2026 in BioMed Research International
Verified
Journal Article
Open access
PDF file
FRFarhana Alam Ripa
Farhana Alam Ripa
AAAjoy Paul Adar
Ajoy Paul Adar
ABAdwiza Chakraborty Bishakha
Adwiza Chakraborty Bishakha
NMNashrah Mustafa
Nashrah Mustafa
MTMehrin Haque Tanisha
Mehrin Haque Tanisha
IBIsrat Jahan Bulbul
Israt Jahan Bulbul
This study investigates the bioactive components and biological activities of the methanolic husk extract of Nypa fruticans Wurmb (MNF) through gas chromatography–mass spectrometry (GC‐MS) analysis. The MNF extract was identified to contain several bioactive components, including alkaloids, glycosides, phenols, tannins, and resins, as established through preliminary phytochemical screening tests. After finding the presence of antioxidant components in the qualitative antioxidative assay, we went to conduct quantitative tests where the total contents of phenolics, flavonoids, and tannins were estimated as 179.43 ± 3.99 mg GAE/g, 179.43 ± 3.99 mg QE/g, and 29.25 ± 0.29 mg TAE/g, respectively. The extract demonstrated notable antioxidant activity in DPPH free radical scavenging (IC 50 36.28 μ g/mL) and ferric reducing antioxidant power (83.27 % ± 0.02 % reduction) assays. The extract demonstrated notable in vitro anti‐inflammatory and antiarthritic properties in a dose‐dependent manner, as indicated by human red blood cell (HRBC) membrane stabilization (74.63 % ± 0.84 % at 5000 μ g/mL) and protein denaturation (88.77 % ± 0.31 % inhibition at 500 μ g/mL), relative to standards. The anti‐inflammatory efficacy of MNF extract was confirmed via an in vivo carrageenan‐induced inflammatory study, showing an 85.49% reduction in edema at the maximum dosage of 600 mg/kg. The extract demonstrated significant ( p < 0.05, p < 0.01, and p < 0.0001) and dose‐dependent analgesic effects in acetic acid–induced writhing and formalin‐induced pain assays. Molecular docking studies conducted with the selected compounds against potential targets identified 1‐(3,6,6‐trimethyl‐1,6,7,7a‐tetrahydrocyclopenta[c]pyran‐1‐yl) ethanone as the best candidate with promising analgesic and anti‐inflammatory potential, demonstrated by its high binding affinity comparable to or exceeding that of the selected standard drugs. Our findings indicate that N. fruticans fruit husk may serve as a viable source of natural chemicals possessing antioxidant, analgesic, anti‐inflammatory, and antiarthritic properties, demonstrating potential therapeutic effects in alleviating diseases associated with inflammatory responses.

17 September 2026 in Discover Applied Sciences
Verified
Journal Article
Open access
PDF file
DKDr. Eva Rahman Kabir
Dr. Eva Rahman Kabir
NMNashrah Mustafa
Nashrah Mustafa
ZSZara Sheikh
Zara Sheikh
MTMehrin Haque Tanisha
Mehrin Haque Tanisha
FTFariha Tasneem
Fariha Tasneem
Asef RajAsef Raj
Asef Raj
Artificial intelligence (AI) is increasingly transforming cancer management by enabling the analysis of complex multimodal data generated across the cancer care continuum. This structured narrative review synthesizes current applications of AI, machine learning, and deep learning in cancer detection, imaging diagnosis, tumor characterization, histopathology, genomics, drug discovery, precision oncology, prognosis, treatment-response prediction, clinical decision support, adherence monitoring, and supportive care. A literature search was conducted using PubMed, Scopus, Web of Science, IEEE Xplore, and Google Scholar for publications from July 2001 to November 2025. From 564 identified records, 234 articles were included in the final thematic synthesis after duplicate removal, title/abstract screening, and full-text assessment. The reviewed evidence shows that AI models, including convolutional neural networks, U-Net-based segmentation models, radiomics approaches, hybrid models, multiple-instance learning, federated learning, large language models, and multimodal frameworks, have demonstrated substantial potential in extracting clinically meaningful patterns from imaging, pathology, genomic, biomarker, and clinical data. These tools may support earlier detection, improved tumor classification, non-invasive molecular profiling, treatment optimization, and personalized decision-making. However, clinical readiness remains uneven, as many models are limited by retrospective designs, dataset heterogeneity, data leakage, overfitting, limited explainability, insufficient external validation, and uncertain generalizability across global healthcare settings. Future progress will require diverse multicenter datasets, standardized annotation, transparent reporting, explainable and hybrid modelling, ethical data governance, regulatory oversight, and post-deployment monitoring. AI should therefore be viewed as clinician-supervised decision support that can strengthen precision oncology when implemented responsibly.

12 August 2026 in Health Science Reports
Verified
Journal Article
Open access
PDF file
ZAZubaier Ahmed
Zubaier Ahmed
NMNashrah Mustafa
Nashrah Mustafa
TSTamanna Sarkar
Tamanna Sarkar
HYHasina Yasmin
Hasina Yasmin
Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and a major contributor to liver‐related morbidity and mortality. Its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), is characterized by hepatocellular injury, inflammation, and fibrosis, which may ultimately progress to cirrhosis and hepatocellular carcinoma. Despite the rapidly increasing global burden of MASH, effective pharmacological therapies remain limited. Lifestyle modification remains the cornerstone of management; however, achieving and maintaining the degree of sustained weight loss required for meaningful histological improvement is challenging in routine clinical practice. Objective: This perspective review evaluates the emerging therapeutic potential of tirzepatide in the management of MASH. Methods: Relevant mechanistic studies, clinical trials, and recent literature published between 2015 and 2025 were reviewed to evaluate the emerging role of tirzepatide and incretin‐based therapies in metabolic liver disease. Results: Tirzepatide is a first‐in‐class dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist that produces substantial metabolic benefits, including improved glycemic control, enhanced insulin sensitivity, and significant weight reduction. These effects directly address key drivers of MASLD and MASH, including hepatic lipid accumulation, insulin resistance, and systemic inflammation. Emerging clinical evidence, particularly from the SYNERGY‐NASH trial, suggests that tirzepatide may promote resolution of steatohepatitis and improvement in fibrosis in patients with biopsy‐confirmed MASH. Conclusion: Tirzepatide represents a promising metabolic disease‐modifying therapy for MASH. Nevertheless, larger and longer‐term clinical studies are needed to establish its durability of benefit, long‐term safety, and optimal role within evolving treatment strategies for metabolic liver disease.